The drug development landscape has undergone a massive transformation in recent years, driven by advancements in bioprocessing and the rise of biologics. Compared to traditional small-molecule drugs, biologics differ significantly in terms of their production methods, molecular complexities and mechanisms of action.1 Their large size and elaborate structures enable these bio-based medicines to target specific biological pathways, offering efficient and tailored treatments for a variety of diseases with minimal off-target effects. However, this complexity also creates significant challenges when it comes to manufacturing, quality control and regulation.2 As a result, manufacturers are continually working to improve the consistency and predictability of bioprocessing.